News
Categories
Sign up
Featured Posts
Archive
- September 2020
- June 2020
- April 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- July 2019
- June 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- May 2018
- April 2018
- March 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- July 2017
- May 2017
- April 2017
- February 2017
- January 2017
Follow Us
Alpha TAU Medical fully supports World Cancer Day 2017 (Saturday, February 4), and is inspired by its efforts to unite the world against this disease; to target misinformation, to raise awareness, and to reduce stigma. Under the campaign theme “We can. I can.” World Cancer Day represents a unique opportunity to draw attention to what can be done to address cancer, save millions of avoidable deaths and, in turn, support global economic growth and development.
Alpha Tau Medical has received IRB approval from IRST (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), in Italy for clinical trials with its Alpha DaRT (Diffusing Alpha–emitters Radiation Therapy) technology for the treatment of Squamous Cell Carcinoma (SCC) in skin cancer. The company is also in the process of finalizing additional protocols for clinical trials in Colorectal and Prostate cancers. Initial trials are due to start within the next few months. Alpha DaRT technology enables the possibility of providing a local alpha-radiotherapy treatment based on alpha emitters, and has several advantages: Highly Potent and Ultra conformal Effective regardless of tumor oxygen
Alpha Tau Medical has initiated its first clinical trials with its Alpha DaRT (Diffusing Alpha–emitters Radiation Therapy) technology for the treatment of Squamous Cell Carcinoma (SCC) in Head, Neck and Skin at the Rabin Medical Center, Petah Tikva outside Tel Aviv. The company is in the process of starting additional clinical trials in prostate cancer, breast cancer, colorectal cancer, gynecological cancer and pancreatic cancer. The Alpha DaRT technology enables the possibility of providing a local alpha-radiation treatment based on alpha emitters and has several advantages: 1. Highly Potent and Ultra conformal 2. Effective regardless of tumor oxygen level 3. Short half-life –